Aclaris Therapeutics (ACRS) announced it has been added to the Nasdaq Biotechnology Index (NBI), effective at the close of trading December 19.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACRS:
- Aclaris Therapeutics management to meet with Cantor
- Aclaris Therapeutics: Promising Pipeline and Strategic Financial Management Justify Buy Rating
- Aclaris Therapeutics Reports Q3 2025 Financial Results
- Aclaris Therapeutics reports Q3 EPS (12c), consensus (14c)
- ACRS Upcoming Earnings Report: What to Expect?